1. Academic Validation
  2. Biotransformation Changes Bioaccumulation and Toxicity of Diclofenac in Aquatic Organisms

Biotransformation Changes Bioaccumulation and Toxicity of Diclofenac in Aquatic Organisms

  • Environ Sci Technol. 2020 Apr 7;54(7):4400-4408. doi: 10.1021/acs.est.9b07127.
Qiuguo Fu 1 Davide Fedrizzi 1 Verena Kosfeld 2 3 Christian Schlechtriem 2 3 Vera Ganz 1 4 Samuel Derrer 1 Daniel Rentsch 5 Juliane Hollender 1 4
Affiliations

Affiliations

  • 1 Eawag, Swiss Federal Institute of Aquatic Science and Technology, 8600 Dübendorf, Switzerland.
  • 2 Fraunhofer Institute for Molecular Biology and Applied Ecology IME, 57392 Schmallenberg, Germany.
  • 3 Institute for Environmental Research (Biology V) 52074 Aachen, Germany.
  • 4 Institute of Biogeochemistry and Pollutant Dynamics, ETH Zürich, 8092 Zürich, Switzerland.
  • 5 EMPA, Swiss Federal Laboratories for Materials Science and Technology, 8600 Dübendorf, Switzerland.
Abstract

Biotransformation plays a crucial role in regulating the bioaccumulation potential and toxicity of organic compounds in organisms but is, in general, poorly understood for emerging contaminants. Here, we have used diclofenac as a model compound to study the impact of biotransformation on the bioaccumulation potential and toxicity in two keystone aquatic invertebrates: Gammarus pulex and Hyalella azteca. In both species, diclofenac was transformed into several oxidation products and conjugates, including two novel products, that is, diclofenac taurine conjugate (DCF-M403) and unexpected diclofenac methyl ester (DCF-M310.03). The ratios of biotransformation products to parent compound were 12-17 for DCF-M403 and 0.01-0.7 for DCF-M310.03 after 24 h exposure. Bioconcentration factors (BCFs) of diclofenac were 0.5 and 3.2 L kgww-1 in H. azteca and G. pulex, respectively, whereas BCFs of DCF-M310.03 was 164.5 and 104.7 L kgww-1, respectively, representing a 25- to 110-fold increase. Acute toxicity of DCF-M310.03 was also higher than the parent compound in both species, which correlated well with the increased bioconcentration potential. The LC50 of diclofenac in H. azteca was 216 mg L-1, while that of metabolite DCF-M310.03 was reduced to only 0.53 mg L-1, representing a 430-fold increase in acute toxicity compared to diclofenac. DCF-M403 is less toxic than its parent compound toward H. azteca, which may be linked to its slightly lower hydrophobicity. Furthermore, the transformation of diclofenac to its methyl ester derivative was explored in crude invertebrate extracts spiked with an S-adenosylmethionine cofactor, revealing possible catalysis by an S-adenosylmethionine-dependent carboxylic acid methyltransferase. Methylation of diclofenac was further detected in fish hepatocytes and human urine, indicating a broader relevance. Therefore, potentially methylated metabolites of polar contaminants should be considered for a comprehensive risk assessment in the future.

Figures
Products